Latest developments in the treatment of lipoprotein (a)
Authors:
- Reyhana YayhaRYReyhana Yayha
- Jeanine E. Roeters van LennepJLJeanine E. Roeters van Lennep
- 1 December 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 25 (6) , 452-460
Abstract
Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. The aim of this review is to provide an overview of treatment options for Lp(a) lowering. Recent studies confirmed that lifestyle intervention and statins do not affect Lp(a) levels, whereas Lp(a) is lowered by oestrogens, niacin, and lipoprotein apheresis. Cholesterol ester transfer protein inhibitors and proprotein convertase subtilisin/kexin type 9 antibodies, currently studied in phase 3 trials, also lower Lp(a) concentrations by 30-50%. However, all of these compounds have modifying effects on multiple lipoprotein classes. An antisense oligonucleotide directed to apolipoprotein (a) has recently been developed to specifically lower circulating Lp(a) levels. This compound lowers Lp(a) mRNA up to 90%, and Lp(a) levels up to 82% in human volunteers independent of Lp(a) levels at baseline. Multiple agents, including the next generation RNA-based antisense therapeutics have Lp(a) lowering properties. However, it remains to be established whether lowering Lp(a) reduces cardiovascular disease events with specific Lp(a) lowering therapies.Keywords
This publication has 36 references indexed in Scilit:
- Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular riskAtherosclerosis, 2014
- The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery diseasePreventive Medicine, 2014
- The Effect of an Energy Restricted Low Glycemic Index Diet on Blood Lipids, Apolipoproteins and Lipoprotein (a) Among Adolescent Girls with Excess Weight: a Randomized Clinical TrialLipids, 2013
- Genetic Associations with Valvular Calcification and Aortic StenosisNew England Journal of Medicine, 2013
- Lipoprotein(a): resurrected by geneticsJournal of Internal Medicine, 2012
- The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetesEndocrine, 2012
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseNew England Journal of Medicine, 2009
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009